000756 新华制药
已收盘 12-19 15:00:00
资讯
新帖
简况
新华制药：公司1年以内应收账款占比超过96%
证券之星 · 12-19 16:48
新华制药：公司1年以内应收账款占比超过96%
新华制药：淄博新华大药店连锁有限公司是旗下药店
证券之星 · 12-18 16:15
新华制药：淄博新华大药店连锁有限公司是旗下药店
新华制药：布洛芬阿司匹林用于流感治疗
证券之星 · 12-09
新华制药：布洛芬阿司匹林用于流感治疗
新华制药：醋酸泼尼松龙原料药获批，市场竞争添 “新翼”
财中社 · 11-27
新华制药：醋酸泼尼松龙原料药获批，市场竞争添 “新翼”
新华制药：公司并不生产奥司他韦原料药
证券之星 · 11-27
新华制药：公司并不生产奥司他韦原料药
新华制药(000756.SZ)：盐酸肾上腺素注射液通过一致性评价
智通财经 · 11-27
新华制药(000756.SZ)：盐酸肾上腺素注射液通过一致性评价
新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准
美股速递 · 11-27
新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准
新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书
智通财经 · 11-25
新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书
新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书
美股速递 · 11-25
新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书
异动快报：新华制药（000756）11月25日13点6分触及涨停板
证券之星 · 11-25
异动快报：新华制药（000756）11月25日13点6分触及涨停板
新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准
智通财经 · 11-17
新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准
新华制药：全球重要解热镇痛类药物生产商
证券之星 · 11-05
新华制药：全球重要解热镇痛类药物生产商
新华制药(000756.SZ)：阿仑膦酸钠口服溶液获得药品注册证书
智通财经 · 10-31
新华制药(000756.SZ)：阿仑膦酸钠口服溶液获得药品注册证书
新华制药 - 收到中国国家药品监督管理局颁发的阿仑膦酸钠口服溶液药品注册证书
美股速递 · 10-31
新华制药 - 收到中国国家药品监督管理局颁发的阿仑膦酸钠口服溶液药品注册证书
新华制药（000756）披露2025年第一次临时股东大会决议暨监事离任公告，10月27日股价下跌0.93%
证券之星 · 10-27
新华制药（000756）披露2025年第一次临时股东大会决议暨监事离任公告，10月27日股价下跌0.93%
新华制药（000756）2025年三季报简析：增收不增利
证券之星 · 10-26
新华制药（000756）2025年三季报简析：增收不增利
新华制药富马酸比索洛尔片获得药品注册证
美股速递 · 10-13
新华制药富马酸比索洛尔片获得药品注册证
新华制药（000756）披露召开2025年第一次临时股东大会通知，9月29日股价下跌1.02%
证券之星 · 09-29
新华制药（000756）披露召开2025年第一次临时股东大会通知，9月29日股价下跌1.02%
新华制药（000756）披露拟召开临时股东大会，9月26日股价下跌1.81%
证券之星 · 09-26
新华制药（000756）披露拟召开临时股东大会，9月26日股价下跌1.81%
新华制药(000756.SZ)：LXH-1211片临床试验申请获批准
智通财经 · 09-25
新华制药(000756.SZ)：LXH-1211片临床试验申请获批准
加载更多
公司概况
公司名称：
山东新华制药股份有限公司
所属行业：
医药制造业
上市日期：
1997-08-06
主营业务：
山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是“新华牌”解热镇痛类药物、心脑血管类、抗感染类及中枢神经类等药物。1个项目获山东省2024年度科技进步二等奖。
发行价格：
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":15.86,"timestamp":1766127828000,"preClose":15.67,"halted":0,"volume":14784064,"delay":0,"changeRate":0.0121,"floatShares":493000000,"shares":690000000,"eps":0.5541,"marketStatus":"已收盘","change":0.19,"latestTime":"12-19 15:00:00","open":15.68,"high":15.87,"low":15.61,"amount":233000000,"amplitude":0.0166,"askPrice":15.87,"askSize":816,"bidPrice":15.86,"bidSize":413,"shortable":0,"etf":0,"ttmEps":0.5541,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.67,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":17.24,"lowLimit":14.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":689776535,"isCdr":false,"pbRate":2.1,"roa":"--","peRate":28.622992,"roe":"5.01%","epsLYR":0.69,"committee":0.097727,"marketValue":10940000000,"turnoverRate":0.03,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-22。","hkstockBrief":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":6.76,"timestamp":1766131686003,"preClose":6.69,"halted":0,"volume":776000,"delay":0,"premium":"-61.47"},"floatMarketCap":7813000000},"requestUrl":"/m/hq/s/000756","defaultTab":"news","newsList":[{"id":"2592152683","title":"新华制药：公司1年以内应收账款占比超过96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592152683?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:48","pubTimestamp":1766134086,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)12月19日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘，公司应收账款等于3年利润，如果出现坏账是否有应对？谢谢新华制药回复：您好！正如公司2025年半年报所描述，公司1年以内应收账款占比超过96%，应收账款结构相对健康。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900024026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2592975545","title":"新华制药：淄博新华大药店连锁有限公司是旗下药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2592975545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592975545?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:15","pubTimestamp":1766045731,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，新华大药房是不是属于新华制药旗下药店，在山东当地有多少连锁店。。经营效益如何？新华制药回复：您好！淄博新华大药店连锁有限公司是新华制药旗下药店，其连锁店主要在山东省内。有关经营情况，请见公司于巨潮资讯网刊载的定期报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800020592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2590917315","title":"新华制药：布洛芬阿司匹林用于流感治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2590917315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590917315?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:00","pubTimestamp":1765267232,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：疫情最近严重，公司有哪些流感药新华制药回复：您好！新华制药是全球重要的解热镇痛类药物生产商，公司生产的布洛芬、阿司匹林等药物广泛应用于流感相关症状的治疗。新华制药有帕拉米韦注射液，这是一种新一代神经氨酸酶抑制剂，可用于治疗全年龄段的甲型或乙型流行性感冒患者。公司产品名录参见公司官网https://www.xhzy.com/。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900019642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2586458322","title":"新华制药：醋酸泼尼松龙原料药获批，市场竞争添 “新翼”","url":"https://stock-news.laohu8.com/highlight/detail?id=2586458322","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586458322?lang=zh_cn&edition=full","pubTime":"2025-11-27 17:05","pubTimestamp":1764234312,"startTime":"0","endTime":"0","summary":"11月27日，新华制药（000756/00719）发布公告，近日公司收到国家药品监督管理局核准签发的醋酸泼尼松龙《化学原料药上市申请批准通知书》。该原料药主要用于治疗过敏性与自身免疫性炎症疾病，包括活动性风湿、类风湿性关节炎等，符合药品注册的有关要求，批准注册后将进一步丰富公司的激素类产品线，提升核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511273576666693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2586243995","title":"新华制药：公司并不生产奥司他韦原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2586243995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586243995?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:57","pubTimestamp":1764233831,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！从网上资料查到贵司现在已经建成全球最大的奥司他韦原料药生产基地。问情况属实吗？另外在当下甲流高发期希望贵司能做出更大社会贡献！顺祝您工作顺利！新华制药回复：您好！新华制药是全球重要的解热镇痛类药物生产商，公司生产的布洛芬、阿司匹林等药物广泛应用于流感相关症状的治疗。公司并不生产奥司他韦原料药，公司产品名录请参见公司官网https://www.xhzy.com/。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700024215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2586248079","title":"新华制药(000756.SZ)：盐酸肾上腺素注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586248079?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:46","pubTimestamp":1764233199,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸肾上腺素注射液《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。本品主要适用于因支气管痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长浸润麻醉用药的作用时间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"1107675950","title":"新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1107675950","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107675950?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:35","pubTimestamp":1764232509,"startTime":"0","endTime":"0","summary":"新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2586423213","title":"新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586423213","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586423213?lang=zh_cn&edition=full","pubTime":"2025-11-25 17:02","pubTimestamp":1764061361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的利丙双卡因乳膏《药品注册证书》。利丙双卡因乳膏是利多卡因和丙胺卡因的复方制剂，用于下列情况的皮肤局部麻醉：针穿刺，例如：置入导管或采血;浅层外科手术，例如：生殖器粘膜，在浅层外科手术或浸润麻醉之前;腿部溃疡清洁/清创术。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"1108747914","title":"新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1108747914","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108747914?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:38","pubTimestamp":1764059911,"startTime":"0","endTime":"0","summary":"新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2586446297","title":"异动快报：新华制药（000756）11月25日13点6分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2586446297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586446297?lang=zh_cn&edition=full","pubTime":"2025-11-25 13:10","pubTimestamp":1764047447,"startTime":"0","endTime":"0","summary":"证券之星11月25日盘中消息，13点6分新华制药触及涨停板。目前价格16.77，上涨7.5%。其所属行业化学制药目前上涨。领涨股为一品红。该股为化学原料药，阿尔茨海默病，医药概念热股，当日化学原料药概念上涨2.42%，阿尔茨海默病概念上涨2.26%，医药概念上涨2.25%。11月24日的资金流向数据方面，主力资金净流入609.34万元，占总成交额2.29%，游资资金净流入561.47万元，占总成交额2.11%，散户资金净流出1170.81万元，占总成交额4.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500016570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2584645529","title":"新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584645529","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584645529?lang=zh_cn&edition=full","pubTime":"2025-11-17 17:01","pubTimestamp":1763370119,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的富马酸伏诺拉生《化学原料药上市申请批准通知书》。该药物主要用于反流性食管炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2581154617","title":"新华制药：全球重要解热镇痛类药物生产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2581154617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581154617?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:33","pubTimestamp":1762313591,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司解热镇痛类药物属于全国头部企业，且生产的奥司他韦也在市场有一定占有率，请问贵公司概念题材里面为什么没有流感板块的介绍呢？新华制药回复：您好！新华制药是全球重要的解热镇痛类药物生产商，公司生产的布洛芬、阿司匹林等药物广泛应用于流感相关症状的治疗。此外，新华制药有帕拉米韦注射液，这是一种新一代神经氨酸酶抑制剂，可用于治疗全年龄段的甲型或乙型流行性感冒患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500013825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2579455559","title":"新华制药(000756.SZ)：阿仑膦酸钠口服溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2579455559","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579455559?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:41","pubTimestamp":1761900105,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)发布公告，公司收到国家药品监督管理局核准签发的阿仑膦酸钠口服溶液(以下简称“本品”)《药品注册证书》。阿仑膦酸钠口服溶液适用于治疗绝经后妇女的骨质疏松症，以预防髋部和脊柱骨折(椎骨压缩性骨折)和男性骨质疏松以增加骨量。根据有关统计数据，2024年阿仑膦酸钠在包括中国公立医院、公立基层医疗机构、零售药店在内的三大终端销售额达人民币7.2亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)：阿仑膦酸钠口服溶液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"1194948924","title":"新华制药 - 收到中国国家药品监督管理局颁发的阿仑膦酸钠口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1194948924","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194948924?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:27","pubTimestamp":1761899263,"startTime":"0","endTime":"0","summary":"新华制药 - 收到中国国家药品监督管理局颁发的阿仑膦酸钠口服溶液药品注册证书","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2578195736","title":"新华制药（000756）披露2025年第一次临时股东大会决议暨监事离任公告，10月27日股价下跌0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578195736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578195736?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:27","pubTimestamp":1761557253,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘，新华制药报收于15.93元，较前一交易日下跌0.93%，最新总市值为109.88亿元。出席会议股东及代理人共532人，代表有表决权股份234,714,588股，占公司有表决权股份总数的34.03%。其中，A股股东同意206,369,729股，H股股东同意20,851,800股，整体同意比例为96.81%。中小股东同意22,357,437股，同意比例74.90%。会议决议合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700024316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2578644683","title":"新华制药（000756）2025年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2578644683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578644683?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:08","pubTimestamp":1761430134,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期新华制药发布2025年三季报。根据财报显示，新华制药增收不增利。截至本报告期末，公司营业总收入67.63亿元，同比上升0.42%，归母净利润2.56亿元，同比下降25.53%。按单季度数据看，第三季度营业总收入21.24亿元，同比上升6.1%，第三季度归母净利润3246.42万元，同比下降58.74%。本次财报公布的各项数据指标表现一般。去年的净利率为5.75%，算上全部成本后，公司产品或服务的附加值一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"1185134887","title":"新华制药富马酸比索洛尔片获得药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=1185134887","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185134887?lang=zh_cn&edition=full","pubTime":"2025-10-13 16:43","pubTimestamp":1760344995,"startTime":"0","endTime":"0","summary":"新华制药富马酸比索洛尔片已获得药品注册证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2571332806","title":"新华制药（000756）披露召开2025年第一次临时股东大会通知，9月29日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571332806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571332806?lang=zh_cn&edition=full","pubTime":"2025-09-29 22:13","pubTimestamp":1759155201,"startTime":"0","endTime":"0","summary":"截至2025年9月29日收盘，新华制药报收于15.6元，较前一交易日下跌1.02%，最新总市值为107.61亿元。公司近日发布公告称，山东新华制药股份有限公司将于2025年10月24日下午2时在山东省淄博市高新区鲁泰大道1号公司会议室召开2025年第一次临时股东大会，股权登记日为2025年10月20日。A股股东可现场参会或通过网络投票，H股股东另行通知。出席登记时间为2025年10月24日下午1:30至2:00，登记地点为公司会议室。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900035251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2570882907","title":"新华制药（000756）披露拟召开临时股东大会，9月26日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570882907","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570882907?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:28","pubTimestamp":1758896886,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，新华制药报收于15.76元，较前一交易日下跌1.81%，最新总市值为108.71亿元。该股当日开盘16.0元，最高16.0元，最低15.75元，成交额达1.25亿元，换手率为1.6%。公司近日发布公告称，山东新华制药股份有限公司第十一届董事会2025年第一次临时会议于2025年9月26日以书面传签方式召开，应参会董事9名，实际参会董事9名。会议审议通过了关于召开2025年第一次临时股东大会的议案，表决结果为9票赞成，0票反对，0票弃权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600038997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2570629440","title":"新华制药(000756.SZ)：LXH-1211片临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2570629440","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570629440?lang=zh_cn&edition=full","pubTime":"2025-09-25 16:48","pubTimestamp":1758790097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的LXH-1211片《药物临床试验批准通知书》，LXH-1211片获准开展肺动脉高压的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","000756","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766167356612,"stockEarnings":[{"period":"1week","weight":-0.0081},{"period":"1month","weight":-0.0394},{"period":"3month","weight":-0.0294},{"period":"6month","weight":0.1006},{"period":"1year","weight":0.0152},{"period":"ytd","weight":0.0243}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0184},{"period":"6month","weight":0.1579},{"period":"1year","weight":0.1544},{"period":"ytd","weight":0.1607}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","registeredCapital":"68977万元","survey":" 山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是“新华牌”解热镇痛类药物、心脑血管类、抗感染类及中枢神经类等药物。1个项目获山东省2024年度科技进步二等奖。","listedPrice":3.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}